Newswise — November 24, 2020 – Medical mistrust is one reason why African American patients are more likely to have regrets about their choice of treatment for prostate cancer, suggests a study in The Journal of Urology®, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Concerns about masculinity also contribute to decision regret among African American men with localized prostate cancer, suggests the new research by Molly DeWitt-Foy, MD, and colleagues of the Cleveland Clinic. “Our findings may help to identify new approaches to reducing racial disparities in risk and treatment outcomes for African American men with prostate cancer,” Dr. DeWitt-Foy comments.

Beliefs about prostate cancer help to explain racial disparities

The study included 1,112 men, average age 63 years, treated for localized prostate cancer between 2010 and 2016. Because their cancer hasn’t spread beyond the prostate gland, patients with localized disease have a choice of treatment options, including active surveillance, hormone therapy, radiation, surgery, or watchful waiting.

About 40 percent of patients in the study were African American, while 60 percent were of other racial/ethnic groups. Most medical characteristics were similar for African American versus non-African American men. Initial treatment consisted of surgery (prostatectomy) in about 50 percent of patients and radiation (brachytherapy) in 42 percent.

The men completed a series of surveys, including a newly designed Prostate Cancer Beliefs Questionnaire (PCBQ). Based on previous studies of racial differences in cultural beliefs regarding medical care, the PCBQ aimed at a better understanding cancer-related beliefs and experience with prostate cancer diagnosis, treatment, recovery and survival.

The outcomes of prostate cancer treatment were generally similar between groups, including problems with urinary incontinence, bowel function, and hormonal symptoms. African American men had lower scores for sexual function compared to non-African American men. Yet despite similar outcomes, African American men had higher average scores for decision regret: about 45 versus 35 (on a 100-point scale).

There were also some racial differences in responses to the PCBQ. “African American men exhibited greater concern about masculinity and more medical mistrust than non-African American men,” Dr. DeWitt-Foy and coauthors write.

African American patients were more likely to say their doctor treated them differently because of their race – although 80 percent of them disagreed with this statement. African American patients were also more likely to feel that screening and treatment for prostate cancer “made them feel like less of a man.”

After adjusting for other factors, African American patients were more than twice as likely to have high decision regret regarding prostate cancer treatment. Medical mistrust and concerns about masculinity explained some of the effect of race on regret scores. Regardless of race, poorer sexual function and worse urinary incontinence – two major side effects of prostate cancer treatment – also predicted higher decision regret scores.

Despite progress over the past 20 years, African American men are still more likely to be diagnosed with, and die from, prostate cancer. The new study sought to better understand patients’ beliefs about prostate cancer, and ultimately to reduce treatment-related decisional regret.

The findings confirm African American men have higher decision regret about their prostate cancer treatment, and suggest these regrets are related to medical mistrust and concerns about masculinity. Dr. DeWitt-Foy and colleagues conclude: “This information may help inform counseling of patients, and has the potential to reduce racial disparities in patients’ experiences with prostate cancer by targeting opportunities for education and improved communication.”

Click here to read “Race, Decisional Regret and Prostate Cancer Beliefs: Identifying Targets to Reduce Racial Disparities in Prostate Cancer.”

DOI: 10.1097/JU.0000000000001385


About The Journal of Urology®

The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing brief editorial comments on the best and most important urology literature worldwide and practice-oriented reports on significant clinical observations. The Journal of Urology® covers the wide scope of urology, including pediatric urology, urologic cancers, renal transplantation, male infertility, urinary tract stones, female urology and neurourology.

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2019 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit, follow us on TwitterFacebookLinkedIn, and YouTube.

Journal Link: The Journal of Urology